GERD / acid reflux
Of the 3 unique stories with a clear outcome, 3 reported it helped (100%).
These are public YouTube testimonials, not clinical evidence. People who tried BPC-157 and got no result rarely post videos — read this as a sample of the positive end of the distribution.
“they've said, 'Man, when I take BPC-157, I have no acid reflux. My digestion works better.'”
“my acid reflux is gone”
“within 24 to 48 hours”
Related research
Nonsteroidal anti-inflammatory drugs-induced failure of lower esophageal and pyloric sphincter and counteraction of sphincters failure with stable gatric pentadecapeptide BPC 157 in rats.
This study found that BPC-157 counteracts the negative effects of nonsteroidal anti-inflammatory drugs (NSAIDs) on the lower esophageal and pyloric sphincters in rats. BPC-157 restored normal pressure values in these sphincters after NSAID-induced failure.
Class side effects: decreased pressure in the lower oesophageal and the pyloric sphincters after the administration of dopamine antagonists, neuroleptics, anti-emetics, L-NAME, pentadecapeptide BPC 157 and L-arginine.
The study found that BPC-157 counteracts the decrease in lower oesophageal and pyloric sphincter pressure caused by dopamine antagonists, neuroleptics, and other substances. BPC-157 also reversed the negative effects of these substances on NO levels and oxidative stress in the plasma, sphincters, and brain tissue.
Esophagogastric anastomosis in rats: Improved healing by BPC 157 and L-arginine, aggravated by L-NAME.
BPC-157 treatment improved healing of esophagogastric anastomosis in rats and counteracted the negative effects of L-NAME, while L-arginine also showed beneficial effects. The study suggests that BPC-157 therapy could correct innate NO-system disability in esophagogastric anastomoses.
BPC 157 therapy to detriment sphincters failure-esophagitis-pancreatitis in rat and acute pancreatitis patients low sphincters pressure.
The study found that BPC-157 therapy can counteract the detrimental effects of sphincter failure, esophagitis, and pancreatitis in rats, and that it may also be beneficial for patients with acute pancreatitis who have low sphincter pressure. The results suggest that BPC-157 could potentially cure esophagitis, sphincter failure, and acute pancreatitis.